2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1211

Biomarkers Predictive of Pain Improvement in Knee Osteoarthritis Subjects Treated with the Anti-IL-1α/β Dual Variable Domain Immunoglobulin ABT-981
Abstract Number: 572

Biopsy Accuracy in Sjögren’s Syndrome: Analysis of 803 Patients Presenting with Sicca Syndrome Referred to Labial Salivary Gland Biopsy
Abstract Number: 226

Biopsy Proven Giant Cell Arteritis in African Descent Populations: Incidence and Characteristics in Martinique, French West Indies
Abstract Number: 2442

Biosimilar Candidate BI 695501 and Adalimumab Reference Product Have Similar Efficacy and Safety in Patients with Moderately-to-Severely Active Rheumatoid Arthritis (RA): 1-Year Results from a Phase III Study
Abstract Number: 1037

Biosimilar Knowledge Among US Rheumatologists – a Survey
Abstract Number: 2287

Biosimilar Use in Children and Young People with Juvenile Idiopathic Arthritis in a Real-World Setting in the United Kingdom
Abstract Number: 2495

Biosimilarity between Humira® and the Biosimilar Candidate SB5 in Product Quality
Abstract Number: 1036

Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Abstract Number: 2110

Blood Group ”a“ Was Increased in FMF Patients and Blood Group ”0“ May be Associated with Colchicine Resistance
Abstract Number: 1918

Blood Levels of Complement Split Product iC3b and C3 Outperform Traditional Biochemical Measures of SLE Disease Activity in Associating with Active and Clinically Meaningful Changes
Abstract Number: 1267

Blood Pressure Control over Time in Childhood-Onset Systemic Lupus Erythematous
Abstract Number: 503

BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis
Abstract Number: 514

BMS-986195, a Novel, Rapidly Acting, Covalent Inhibitor of Bruton’s Tyrosine Kinase: Safety, Pharmacokinetic and Pharmacodynamic Profiles in Healthy Participants
Abstract Number: 2961

Body Composition and Myokine Levels in Juvenile Dermatomyositis and Associations with Physical Function
Abstract Number: 1634

Body Mass Index and Disease Activity in Systemic Lupus Erythematosus- a Paradoxical Relationship?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].